Network-based rTMS in Alzheimer's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-03-21

Study Completion Date

2024-03-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Severe alterations of brain networks connectivity have been described in Alzheimer's disease (AD). Repetitive Transcranial Magnetic Stimulation (rTMS) has gained evidence as an effective tool to modulate brain networks connectivity, leading to a recovery or reorganization of both local and remote brain regions functionally connected to the stimulated area. The investogators propose an innovative tailored network-based rTMS treatment to ameliorate cognitive symptoms in mild AD, through the boosting of connectivity within brain networks affected by AD pathophysiology. The combination of the proposed intervention with an integrated multi-modal imaging approach will allow to evaluate the neural mechanisms underlying the clinical response to the treatment and to define quantitative markers of clinical impact on AD. If successful, the present proposal would immediately impact on patient's quality of life, with important implications for the time and costs of delivery of rehabilitative services.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Targeting Default Mode Network Dysfunction in Persons At Risk of Alzheimer's Disease with Non-invasive Techniques

NCT05984446

Alzheimer Disease

COMPLETED NA

Applying Non-invasive Brain Stimulation in Alzheimer's Rehabilitation

NCT04866979

Alzheimer Disease Mild Cognitive Impairment

UNKNOWN NA

Repetitive TMS of the Default Mode Network in AD

NCT03778151

Alzheimer Disease

COMPLETED NA

Efficacy and Safety of Transcranial Magnetic Stimulation in Treatment of Alzheimer's Disease

NCT07324161

Alzheimer s Disease

RECRUITING NA

Repetitive Transcranial Magnetic Stimulation for Dementia

NCT02621424

Dementia Mild Cognitive Impairment

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Currently, no effective cure is available for Alzheimer's disease (AD). Repetitive Transcranial Magnetic Stimulation (rTMS) has gained increasing attention as a potential treatment for various neurological and psychiatric disorders, but available rTMS studies are flawed by inaccurate anatomical targeting, inadequate sample size, unsatisfactory controls and lacking blindness. To date, the elective target area of rTMS interventions in AD has been the dorsolateral prefrontal cortex (DLPFC), a core area of the Central Executive network (CEN), which plays a key role in regulating executive functions, attention and working memory. While the CEN has recently been described as dysfunctional in AD, AD pathophysiology has been mainly associated with the breakdown of the Default Mode network (DMN) and with structural disconnection of its parietal nodes. The DMN plays a crucial role in episodic memory retrieval and incorporates various brain regions, among which parietal areas are highly connected with the rest of the brain. The present multicenter, double-blind, randomized and placebo-controlled study has the ambition to provide evidence of the efficacy of two tailored network-based rTMS treatments in mild AD, through the enhancement of connectivity of CEN and DMN. Innovative integrated multi-modal imaging investigations will further enrich this proposal allowing to identify quantifiable markers underlying the clinical impact of rTMS on AD.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer Disease, Late Onset Alzheimer Disease Cognitive Deterioration

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

After recruitment, patients will be randomized and assigned to one of three rTMS treatments: DMN (N=20), CEN (N=20) or placebo (N=20). The rTMS treatment will consist of 2 phases: an intensive phase and a maintenance phase. The intensive phase will involve 3 weeks of treatment, 5 days per week (15 sessions in total). The maintenance will consist of 1 session of treatment every 2 weeks for 5 months (10 sessions in total). Overall, the patients will undergo 25 sessions of rTMS delivered over 6 months. At baseline (T0), at the end of the intensive phase (T1) and at the end of the maintenance phase (T2) all patients will undergo a clinical and cognitive assessment and a multi-modal imaging data collection.

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors

The study will be a double blind trial, i.e. both patients and clinicians involved in the assessment will be blind to treatment allocation.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Default Mode Network (DMN)

The treatment will consist in the individually tailored stimulation of a DMN node (i.e. left inferior parietal lobe).

Group Type EXPERIMENTAL

rTMS

Intervention Type DEVICE

25 min of high frequency (20 Hz) repetitive TMS applied at 100% of resting motor threshold (rMT).

Central Executive Network (CEN)

The treatment will consist in the individually tailored stimulation of a CEN node (i.e. left dorsolateral prefrontal cortex).

Group Type EXPERIMENTAL

rTMS

Intervention Type DEVICE

25 min of high frequency (20 Hz) repetitive TMS applied at 100% of resting motor threshold (rMT).

Placebo

The treatment will consist in targeting the upper part of the scalp (i.e. CZ) while using a sham rTMS coil.

Group Type PLACEBO_COMPARATOR

Sham rTMS

Intervention Type DEVICE

Placebo intervention will consist in the same procedure but using a sham rTMS coil.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

rTMS

25 min of high frequency (20 Hz) repetitive TMS applied at 100% of resting motor threshold (rMT).

Intervention Type DEVICE

Sham rTMS

Placebo intervention will consist in the same procedure but using a sham rTMS coil.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Mini-Mental State Examination score \>=16, \<=24
* Anti-cholinesterase treatment for at least 3 months prior the start date

Exclusion Criteria

* Enrollment in other clinical and pharmacological trials
* Previous evidence of any other CNS disorder (e.g. epilepsy, infectious diseases, frontotemporal, Parkinson or Pick's disease)
* History of major psychiatric disorders
* History of alchol or substance abuse
* Stress-related skin problems
* Current consumption of psychiatric medication
* Presence of metal implants or any implanted electronics

Minimum Eligible Age

55 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No